Langopept Phase I dose-escalation registration
Planned study · 2019
- Registered population or design
- 42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.
- Results availability
- MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.
Reported findings and study design
The patent gives no measured outcomes
Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.
Dose, route and schedule
Single and then repeated escalating intramuscular doses versus placebo. The registry lists a 5 mg vial. Dose levels, intervals and duration are unavailable.
Protocol source ↗ · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned enrollment | 42 healthy volunteers |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.
Source details
Trial registry reproduction
ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
Sources checked
Citation
MedInvest. Langopept Phase I dose-escalation registration Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019.